NCT01502345View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Hemorrhagic Fever With Renal Syndrome
Interventions
BIOLOGICAL

Vaccine/device combination for prevention of HFRS

PUUV DNA Vaccine, 2.0mg/ml TDS-IM injection HTNV DNA Vaccine, 2.0 mg/ml TDS-IM injection HTNV + PUUV Vaccine mixture, 1.0mg/mL + 1.0mg/ml TDS-IM injection

Trial Locations (1)

20910

Walter Reed Army Institute of Research, Silver Spring

Sponsors
All Listed Sponsors
collaborator

US Army Medical Research Institute of Infectious Diseases

FED

collaborator

United States Army Medical Materiel Development Activity

FED

collaborator

Ichor Medical Systems Incorporated

INDUSTRY

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

U.S. Army Medical Research and Development Command

FED

NCT01502345 - Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines | Biotech Hunter | Biotech Hunter